RNA toxicity in human disease and animal models: From the uncovering of a new mechanism to the development of promising therapies

被引:52
|
作者
Sicot, Geraldine
Gomes-Pereira, Mario [1 ]
机构
[1] Hop Necker Enfants Malad, INSERM, U781, F-75015 Paris, France
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2013年 / 1832卷 / 09期
关键词
Animal model; RNA toxicity; Trinucleotide repeat; Microsatellite expansion; Myotonic dystrophy; RNA splicing; MYOTONIC-DYSTROPHY TYPE-1; PRE-MESSENGER-RNA; EXPANDED CTG REPEATS; FRAGILE-X PREMUTATION; 3 UNTRANSLATED REGION; TRINUCLEOTIDE REPEAT; SPINOCEREBELLAR ATAXIA; SKELETAL-MUSCLE; CUG REPEATS; TRIPLET-REPEAT;
D O I
10.1016/j.bbadis.2013.03.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutant ribonucleic acid (RNA) molecules can be toxic to the cell, causing human disease through trans-acting dominant mechanisms. RNA toxicity was first described in myotonic dystrophy type 1, a multisystemic disorder caused by the abnormal expansion of a non-coding trinucleotide repeat sequence. The development of multiple and complementary animal models of disease has greatly contributed to clarifying the complex disease pathways mediated by toxic RNA molecules. RNA toxicity is not limited to myotonic dystrophy and spreads to an increasing number of human conditions, which share some unifying pathogenic events mediated by toxic RNA accumulation and disruption of RNA-binding proteins. The remarkable progress in the dissection of disease pathobiology resulted in the rational design of molecular therapies, which have been successfully tested in animal models. Toxic RNA diseases, and in particular myotonic dystrophy, clearly illustrate the critical contribution of animal models of disease in translational research: from gene mutation to disease mechanisms, and ultimately to therapy development. This article is part of a Special Issue entitled: Animal Models of Disease. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1390 / 1409
页数:20
相关论文
共 50 条
  • [1] RNA Splicing and Disease: Animal Models to Therapies
    Montes, Matias
    Sanford, Brianne L.
    Comiskey, Daniel F.
    Chandler, Dawn S.
    TRENDS IN GENETICS, 2019, 35 (01) : 68 - 87
  • [2] Animal models of schizophrenia for the development of new therapies
    Mori, N
    Suzuki, K
    Iwata, Y
    Matsuzaki, H
    Watanabe, T
    Wakuda, T
    Dote, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 21P - 21P
  • [3] Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies
    Wang, Lin-hui
    Qin, Zheng-hong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (10) : 1287 - 1302
  • [4] Animal models of leukodystrophy: a new perspective for the development of therapies
    Rutherford, Holly A.
    Hamilton, Noemie
    FEBS JOURNAL, 2019, 286 (21) : 4176 - 4191
  • [5] Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies
    Lin-hui WANG~2 Zheng-hong QIN~(3
    Acta Pharmacologica Sinica, 2006, (10) : 1287 - 1302
  • [6] Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies
    Lin-hui Wang
    Zheng-hong Qin
    Acta Pharmacologica Sinica, 2006, 27 : 1287 - 1302
  • [7] Predicting human toxicity from animal models
    Park, K
    TOXICOLOGY, 2001, 168 (01) : 44 - 45
  • [8] New combination therapies from animal to human
    Brunello, N
    Alboni, S
    Benatti, C
    Capone, G
    Tascedda, E
    Blom, JMC
    Mendlewicz, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S348 - S348
  • [9] Large animal models and new therapies for glycogen storage disease
    Brooks, Elizabeth D.
    Koeberl, Dwight D.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2015, 38 (03) : 505 - 509
  • [10] Are the animal models of Parkinson's disease suitable for development of neuroprotective therapies?
    Kirik, D.
    Ulusoy, A.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 63 - 63